One-day famciclovir vs. placebo in patient-initiated episodic treatment of recurrent genital herpes in immunocompetent Black patients

References

• Xu F, Sternberg MR, Kottiri BJ, et al. Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States. JAMA 2006;296:964-73
   PubMed Web of Science ®Google Scholar
• Smith JS, Robinson NJ. Age-specific prevalence of infection with herpes simplex virus types 2 and 1: a global review. J Infect Dis 2002;186(Suppl. 1):S3-28
   PubMed Web of Science ®Google Scholar
• Mertz GJ. Epidemiology of genital herpes infections. Infect Dis Clin North Am 1993;7:825-39
   PubMed Web of Science ®Google Scholar
• Johnson RE, Nahmias AJ, Magder LS, et al. A seroepidemiologic survey of the prevalence of herpes simplex virus type 2 infection in the United States. N Engl J Med 1989;321:7-12
   PubMed Web of Science ®Google Scholar
• Schillinger JA, McKinney CM, Garg R, et al. Seroprevalence of herpes simplex virus type 2 and characteristics associated with undiagnosed infection: New York City, 2004. Sex Transm Dis 2008;35:599-606
   PubMed Web of Science ®Google Scholar
• Baeten JM, Strick LB, Lucchetti A, et al. Herpes simplex virus (HSV)-suppressive therapy decreases plasma and genital HIV-1 levels in HSV-2/HIV-1 coinfected women: a randomized, placebo-controlled, cross-over trial. J Infect Dis 2008;198:1804-8
   PubMed Web of Science ®Google Scholar
• Zuckerman RA, Lucchetti A, Whittington WL, et al. HSV suppression reduces seminal HIV-1 levels in HIV-1/HSV-2 co-infected men who have sex with men. AIDS 2009;23:479-83
   PubMed Web of Science ®Google Scholar
• Tyring S, Richwald G, Hamed K. Single-day therapy: an expert opinion on a recent development for the episodic treatment of recurrent genital herpes. Arch Gynecol Obstet 2007;275:1-3
   PubMedGoogle Scholar
• Workowski KA, Berman SM. Sexually transmitted diseases treatment guidelines, 2006. Centers for Disease Control and Prevention. MMWR Recomm Rep. 2006;55(RR-11):1-94
   PubMedGoogle Scholar
• Beauman JG. Genital herpes: a review. Am Fam Physician 2005;72:1527-34
   PubMed Web of Science ®Google Scholar
• Brown ZA, Kern ER, Spruance SL, et al. Clinical and virologic course of herpes simplex genitalis. West J Med 1979;130:414-21
   PubMedGoogle Scholar
• Spruance SL. Herpes simplex labialis. In: Sacks SL, Straus SE, Whitley RJ, Griffiths PD, editors. Clinical management of herpes viruses. Amsterdam, Netherlands: IOS Press, 1995: 3-42
   Google Scholar
• Leone PA, Trottier S, Miller JM. Valacyclovir for episodic treatment of genital herpes: a shorter 3-day treatment course compared with 5-day treatment. Clin Infect Dis 2002;34:958-62
   PubMed Web of Science ®Google Scholar
• Strand A, Patel R, Wulf HC, et al. International Valaciclovir HSV Study Group. Aborted genital herpes simplex virus lesions: findings from a randomised controlled trial with valaciclovir. Sex Transm Infect 2002;78:435-9
   PubMed Web of Science ®Google Scholar
• Wald A, Carrell D, Remington M, et al. Two-day regimen of acyclovir for treatment of recurrent genital herpes simplex virus type 2 infection. Clin Infect Dis 2002;34:944-8
   PubMed Web of Science ®Google Scholar
• Bodsworth N, Bloch M, McNulty A, et al. 2-day versus 5-day famciclovir as treatment of recurrences of genital herpes – results of the FaST study. Sexual Health 2008;5:219-25
   PubMed Web of Science ®Google Scholar
• Aoki FY, Tyring S, Diaz-Mitoma F, et al. Single-day, patient-initiated famciclovir therapy for recurrent genital herpes: a randomized, double blind, placebo trial. Clin Infect Dis 2006;42:8-13
   PubMed Web of Science ®Google Scholar
• Abudalu M, Tyring S, Koltun W, et al. Single-day, patient-initiated famciclovir therapy versus 3-day valacyclovir regimen for recurrent genital herpes: a randomized, double-blind, comparative trial. Clin Infect Dis 2008;47:651-8
   PubMed Web of Science ®Google Scholar
• Vinh DC, Aoki FY. Famciclovir for the treatment of recurrent genital herpes: a clinical and pharmacological perspective. Expert Opin Pharmacother 2006;7:2271-86
   PubMed Web of Science ®Google Scholar
• Sarisky RT, Bacon TH, Boon RJ, et al. Profiling penciclovir susceptibility and prevalence of resistance of herpes simplex virus isolates across eleven trials. Arch Virol 2003;148:1757-69
   PubMed Web of Science ®Google Scholar
• Reyes M, Shaik NS, Graber JM, et al. Acyclovir-resistant genital herpes among persons attending sexually transmitted disease and human immunodeficiency virus clinics. Arch Intern Med 2003;163:76-80
   PubMed Web of Science ®Google Scholar
• Bodsworth N, Fife K, Koltun W, et al. Single-day famciclovir for the treatment of genital herpes: follow-up results of time to next recurrence and assessment of antiviral resistance. Curr Med Res Opin 2009;25:483-7
   PubMed Web of Science ®Google Scholar
• Gill KS, Wood MJ. The clinical pharmacokinetics of famciclovir. Clin Pharmacokinet 1996;31:1-8
   PubMed Web of Science ®Google Scholar
• Pue MA, Benet LZ. Pharmacokinetics of famciclovir in man. Antiviral Chem Chemother 1993;4(Suppl. 1):47-55
   Web of Science ®Google Scholar
• Pue MA, Pratt SK, Fairless AJ, et al. Linear pharmacokinetics of penciclovir following administration of single oral doses of famciclovir 125, 250, 500 and 750 mg to healthy volunteers. J Antimicrob Chemother 1994;33:119-27
   PubMed Web of Science ®Google Scholar
• Simpson D, Lyseng-Williamson KA. Famciclovir. A review of its use in herpes zoster and genital and orolabial herpes. Drugs 2006;66:2397-416
   PubMed Web of Science ®Google Scholar
• Boike SC, Pue M, Audet PR, et al. Pharmacokinetics of famciclovir in subjects with chronic hepatic disease. J Clin Pharmacol 1994;34:1199-207
   PubMed Web of Science ®Google Scholar
• Kaiser G. Pharmacokinetics of famciclovir in Black and Caucasian subjects (data on file, Novartis Pharma AG). July 14, 2009. File number: 090095a881fde4ca
   Google Scholar
• Corey L, Huang ML, Selke S, et al. Differentiation of herpes simplex virus types 1 and 2 in clinical samples by a real-time taqman PCR assay. J Med Virol 2005;76:350-5
   PubMed Web of Science ®Google Scholar
• Prichard MN, Keith KA, Johnson MP, et al. Selective phosphorylation of antiviral drugs by vaccinia virus thymidine kinase. Antimicrob Agents Chemother 2007;51:1795-803
   PubMed Web of Science ®Google Scholar
• Lehmann EL. Nonparametrics: statistical methods based on ranks. San Francisco: Holden–Day, 1975
   Google Scholar
• Sperling RS, Fife KH, Warren TJ, et al. The effect of daily valacyclovir suppression on herpes simplex virus type 2 viral shedding in HSV-2 seropositive subjects without a history of genital herpes. Sex Transm Dis 2008;35:286-90
   PubMed Web of Science ®Google Scholar
• Fife KH, Barbarash RA, Rudolph T, et al. Valaciclovir versus acyclovir in the treatment of first-episode genital herpes infection. Results of an international, multicenter, double-blind, randomized clinical trial. The Valaciclovir International Herpes Simplex Virus Study Group. Sex Transm Dis 1997;24:481-6
   PubMed Web of Science ®Google Scholar
• Fife KH, Warren TJ, Ferrera RD, et al. Effect of valacyclovir on viral shedding in immunocompetent patients with recurrent herpes simplex virus 2 genital herpes: a US-based randomized, double-blind, placebo-controlled clinical trial. Mayo Clin Proc 2006;81:1321-7
   PubMed Web of Science ®Google Scholar
• Gebo KA, Kalyani R, Moore RD, et al. The incidence of, risk factors for, and sequelae of herpes zoster among HIV patients in the highly active antiretroviral therapy era. J Acquir Immune Defic Syndr 2005;40:169-74
   PubMed Web of Science ®Google Scholar
• Arora A, Mendoza N, Brantley J, et al. Double-blind study comparing 2 dosages of valacyclovir hydrochloride for the treatment of uncomplicated herpes zoster in immunocompromised patients 18 years of age and older. J Infect Dis 2008;197:1289-95
   PubMed Web of Science ®Google Scholar
• DeJesus E, Wald A, Warren T, et al. Valacyclovir for the suppression of recurrent genital herpes in human immunodeficiency virus-infected subjects. J Infect Dis 2003;188:1009-16
   PubMed Web of Science ®Google Scholar
• Warren T, Harris J, Brennan CA. Efficacy and safety of valacyclovir for the suppression and episodic treatment of herpes simplex virus in patients with HIV. Clin Infect Dis 2004;39(Suppl. 5):S258-66
   PubMed Web of Science ®Google Scholar
• Cowan FM, Pascoe SJ, Barlow KL, et al. A randomised placebo-controlled trial to explore the effect of suppressive therapy with acyclovir on genital shedding of HIV-1 and herpes simplex virus type 2 among Zimbabwean sex workers. Sex Transm Infect 2008;84:548-53
   PubMed Web of Science ®Google Scholar
• Delany S, Mlaba N, Clayton T, et al. Impact of aciclovir on genital and plasma HIV-1 RNA in HSV-2/HIV-1 co-infected women: a randomized placebo-controlled trial in South Africa. AIDS 2009;23:461-9
   PubMed Web of Science ®Google Scholar
• Watson-Jones D, Weiss HA, Rusizoka M, et al. Effect of herpes simplex suppression on incidence of HIV among women in Tanzania. N Engl J Med 2008;358:1560-71
   PubMed Web of Science ®Google Scholar
• Celum C, Wald A, Hughes J, et al. Effect of aciclovir on HIV-1 acquisition in herpes simplex virus 2 seropositive women and men who have sex with men: a randomised, double-blind, placebo-controlled trial. Lancet 2008;371:2109-19
   PubMed Web of Science ®Google Scholar
• Ouedraogo A, Nagot N, Vergne L, et al. Impact of suppressive herpes therapy on genital HIV-1 RNA among women taking antiretroviral therapy: a randomized controlled trial. AIDS 2006;20:2305-13
   PubMed Web of Science ®Google Scholar
• Spruance SL, Tyring SK, DeGregorio B, et al. A large-scale, placebo-controlled, dose-ranging trial of peroral valaciclovir for episodic treatment of recurrent herpes genitalis. Valaciclovir HSV Study Group. Arch Intern Med 1996;156:1729-35
   PubMed Web of Science ®Google Scholar